Phase 3 Head and Neck Cancer Trial, Recruiting NCT06641791 Sponsor: Canadian Cancer Trials Group Condition: Head and Neck Cancer
Back to Head And Neck Cancer

Phase 3 Head and Neck Cancer Trial, Recruiting

NCT06641791
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have been diagnosed (confirmed by tissue testing) with a type of cancer called squamous cell carcinoma affecting the moist lining of the head and neck area — specifically from the throat (oro/hypopharynx), mouth, upper voice box, the sinus near the cheek, nasal cavity, or from an unknown starting point
  • People whose cancer has been assessed at any stage from early to advanced (covering a range of tumour and lymph node classifications)
  • People whose treating cancer doctor has determined they are not suitable for radiation therapy given with the goal of curing the cancer
  • People who score below 14 on a specific older adult health assessment tool called the Geriatric 8 (confirm with trial site)
  • People aged 18 years or older
  • People who have had a CT or MRI scan of the head and neck within the 8 weeks before joining the trial
  • People who have had a chest CT or chest x-ray (a PET-CT scan may also be accepted if it includes a diagnostic-quality CT)
  • People with a physical performance rating of 0 to 3 on a standard scale used in cancer research called the ECOG scale, which ranges from fully active (0) to limited self-care (3)
  • People who are capable of having children and have agreed to use a highly effective method of contraception during the treatment period
  • People who have had a previous cancer, as long as that prior cancer or its treatment is not expected to interfere with this trial's treatment or results

Who may not be able to join:

  • People whose cancer started in the nasopharynx (upper part of the throat behind the nose)
  • People who have previously received systemic treatment for cancer, including immunotherapy
  • People who have previously had radiation therapy to the head and neck area, with an exception for superficial skin-only radiotherapy that does not overlap with the area to be treated in this trial
  • People with a previous head and neck cancer (skin cancers of the head and neck are excluded from this rule)
  • People whose tumour is located in an area considered higher risk for serious side effects from the type of radiation used in this trial — including the lower voice box, a certain part of the lower throat, the area behind the voice box, the upper food pipe, or tumours that wrap all the way around the throat, are close to the brain or eyes, or where any single tumour mass is larger than 8 cm
  • People whose cancer has spread to more than 2 lymph node regions in the neck (assessed according to specific anatomical rules — confirm details with trial site)
  • People whose tumour cannot be clearly seen on CT or MRI scans
  • People with clear evidence — either on scans or clinically — that the cancer has spread to distant parts of the body
  • People with a connective tissue condition called scleroderma or CREST syndrome

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ian Poon, Odette Cancer Centre, Sunnybrook Health Sciences, UHN, Toronto, ON Canada

Phone: 613-533-6430

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Canadian Cancer Trials Group
Registry
ClinicalTrials.gov
Start date
7 April 2025
Est. completion
1 January 2031

Where this trial is recruiting

🇨🇦 Canada

Primary endpoints

Overall Survival estimated according to Kaplan-Meier's methodology

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov